Literature DB >> 28660606

Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.

A A Verhaegen1,2, L F Van Gaal3.   

Abstract

Weight gain is a common side effect of many widely used drugs. Weight gain of a few kilograms to an increase of 10% or more of initial body weight has been described. Not only the weight gain as such puts a burden on the health risks of the involved patients, the accompanying increase in the incidence of the metabolic syndrome, type 2 diabetes mellitus, and cardiovascular risk factors urges the caregiver to identify and to closely monitor the patients at risk. In this review, the different classes of drugs with significant weight gaining properties and the metabolic consequences are described. Specific attention is given to pathogenetic mechanisms underlying the metabolic effects and to potential therapeutic measures to prevent them.

Entities:  

Keywords:  Antipsychotics; Drug-induced obesity; Mechanisms; Metabolic syndrome; Therapy

Mesh:

Substances:

Year:  2017        PMID: 28660606     DOI: 10.1007/s40618-017-0719-6

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  99 in total

Review 1.  Antidepressants and body weight: a comprehensive review and meta-analysis.

Authors:  Alessandro Serretti; Laura Mandelli
Journal:  J Clin Psychiatry       Date:  2010-10       Impact factor: 4.384

2.  Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective.

Authors:  Gabriela Balf; Thomas D Stewart; Richard Whitehead; Ross A Baker
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 3.  Glucocorticoids in adipocytes stimulate visceral obesity.

Authors:  George Wolf
Journal:  Nutr Rev       Date:  2002-05       Impact factor: 7.110

4.  Weight gain related to treatment with atypical antipsychotics is due to activation of PKC-β.

Authors:  C Pavan; V Vindigni; L Michelotto; A Rimessi; G Abatangelo; R Cortivo; P Pinton; B Zavan
Journal:  Pharmacogenomics J       Date:  2009-12-22       Impact factor: 3.550

Review 5.  Bupropion for weight reduction.

Authors:  Kishore M Gadde; Glen L Xiong
Journal:  Expert Rev Neurother       Date:  2007-01       Impact factor: 4.618

Review 6.  Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.

Authors:  Juan Pablo Domecq; Gabriela Prutsky; Aaron Leppin; M Bassam Sonbol; Osama Altayar; Chaitanya Undavalli; Zhen Wang; Tarig Elraiyah; Juan Pablo Brito; Karen F Mauck; Mohammed H Lababidi; Larry J Prokop; Noor Asi; Justin Wei; Salman Fidahussein; Victor M Montori; Mohammad Hassan Murad
Journal:  J Clin Endocrinol Metab       Date:  2015-01-15       Impact factor: 5.958

7.  Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.

Authors:  J K Belanoff; C M Blasey; R D Clark; R L Roe
Journal:  Diabetes Obes Metab       Date:  2010-06       Impact factor: 6.577

8.  Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis.

Authors:  Peter K Wung; Troy Anderson; Kevin R Fontaine; Gary S Hoffman; Ulrich Specks; Peter A Merkel; Robert Spiera; John C Davis; E William St Clair; W Joseph McCune; John H Stone
Journal:  Arthritis Rheum       Date:  2008-05-15

9.  Body weight changes with beta-blocker use: results from GEMINI.

Authors:  Franz H Messerli; David S H Bell; Vivian Fonseca; Richard E Katholi; Janet B McGill; Robert A Phillips; Philip Raskin; Jackson T Wright; Sripal Bangalore; Fred K Holdbrook; Mary Ann Lukas; Karen M Anderson; George L Bakris
Journal:  Am J Med       Date:  2007-07       Impact factor: 4.965

10.  National trends in off-label use of atypical antipsychotics in children and adolescents in the United States.

Authors:  Minji Sohn; Daniela C Moga; Karen Blumenschein; Jeffery Talbert
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

View more
  13 in total

1.  Role of Serotonin Transporter in Antidepressant-Induced Diabetes Mellitus: A Pharmacoepidemiological-Pharmacodynamic Study in VigiBase®.

Authors:  Thi Thu Ha Nguyen; Anne Roussin; Vanessa Rousseau; Jean-Louis Montastruc; François Montastruc
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

2.  Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE).

Authors:  M Caprio; M Infante; E Moriconi; A Armani; A Fabbri; G Mantovani; S Mariani; C Lubrano; E Poggiogalle; S Migliaccio; L M Donini; S Basciani; A Cignarelli; E Conte; G Ceccarini; F Bogazzi; L Cimino; R A Condorelli; S La Vignera; A E Calogero; A Gambineri; L Vignozzi; F Prodam; G Aimaretti; G Linsalata; S Buralli; F Monzani; A Aversa; R Vettor; F Santini; P Vitti; L Gnessi; U Pagotto; F Giorgino; A Colao; A Lenzi
Journal:  J Endocrinol Invest       Date:  2019-05-20       Impact factor: 4.256

3.  Use of prescription medications associated with weight gain among US adults, 1999-2018: A nationally representative survey.

Authors:  Craig M Hales; Qiuping Gu; Cynthia L Ogden; Susan Z Yanovski
Journal:  Obesity (Silver Spring)       Date:  2021-12-14       Impact factor: 9.298

Review 4.  Obesity II: Establishing causal links between chemical exposures and obesity.

Authors:  Jerrold J Heindel; Sarah Howard; Keren Agay-Shay; Juan P Arrebola; Karine Audouze; Patrick J Babin; Robert Barouki; Amita Bansal; Etienne Blanc; Matthew C Cave; Saurabh Chatterjee; Nicolas Chevalier; Mahua Choudhury; David Collier; Lisa Connolly; Xavier Coumoul; Gabriella Garruti; Michael Gilbertson; Lori A Hoepner; Alison C Holloway; George Howell; Christopher D Kassotis; Mathew K Kay; Min Ji Kim; Dominique Lagadic-Gossmann; Sophie Langouet; Antoine Legrand; Zhuorui Li; Helene Le Mentec; Lars Lind; P Monica Lind; Robert H Lustig; Corinne Martin-Chouly; Vesna Munic Kos; Normand Podechard; Troy A Roepke; Robert M Sargis; Anne Starling; Craig R Tomlinson; Charbel Touma; Jan Vondracek; Frederick Vom Saal; Bruce Blumberg
Journal:  Biochem Pharmacol       Date:  2022-04-05       Impact factor: 6.100

Review 5.  Precision Medicine and Obesity.

Authors:  Maria Daniela Hurtado A; Andres Acosta
Journal:  Gastroenterol Clin North Am       Date:  2021-01-05       Impact factor: 3.806

6.  A phenotypic Caenorhabditis elegans screen identifies a selective suppressor of antipsychotic-induced hyperphagia.

Authors:  Anabel Perez-Gomez; Maria Carretero; Natalie Weber; Veronika Peterka; Alan To; Viktoriya Titova; Gregory Solis; Olivia Osborn; Michael Petrascheck
Journal:  Nat Commun       Date:  2018-12-10       Impact factor: 14.919

Review 7.  Medications that cause weight gain and alternatives in Canada: a narrative review.

Authors:  Sean Wharton; Lilian Raiber; Kristin J Serodio; Jasmine Lee; Rebecca Ag Christensen
Journal:  Diabetes Metab Syndr Obes       Date:  2018-08-21       Impact factor: 3.168

8.  Effect of Obesogenic Medications on Weight-Loss Outcomes in a Behavioral Weight-Management Program.

Authors:  Athanasios Desalermos; Baylee Russell; Cecilia Leggett; Amelia Parnell; Kathleen Ober; Kelley Hagerich; Cindy Gerlan; Gelareh Ganji; Euyhyun Lee; James A Proudfoot; Eduardo Grunvald; Samir Gupta; Samuel B Ho; Amir Zarrinpar
Journal:  Obesity (Silver Spring)       Date:  2019-05       Impact factor: 5.002

9.  Metabolomic profiles associated with a mouse model of antipsychotic-induced food intake and weight gain.

Authors:  Rizaldy C Zapata; Sara Brin Rosenthal; Kathleen Fisch; Khoi Dao; Mohit Jain; Olivia Osborn
Journal:  Sci Rep       Date:  2020-10-29       Impact factor: 4.379

10.  Characteristics associated with polypharmacy in people with type 2 diabetes: the Dutch Diabetes Pearl cohort.

Authors:  S van Oort; F Rutters; M F Warlé-van Herwaarden; M T Schram; C D Stehouwer; C J Tack; E J Abbink; B H Wolffenbuttel; M M van der Klauw; J H DeVries; S E Siegelaar; E J Sijbrands; B Özcan; H W de Valk; B Silvius; M A Schroijen; I M Jazet; A J van Ballegooijen; J W J Beulens; P J Elders; C Kramers
Journal:  Diabet Med       Date:  2020-10-17       Impact factor: 4.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.